New drug tested in patients with liver disease: safety first
NCT ID NCT04534699
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study looked at how the drug KBP-5074 behaves in people with moderate liver impairment compared to healthy volunteers. Twelve adults received a single dose, and researchers monitored safety and drug levels in the blood. The goal was to see if liver problems change how the drug is processed, which is important for future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KBP-5074 (a tablet drug)
What this could lead to
If successful, this study could help doctors understand how to safely dose KBP-5074 in patients with liver problems.
What could go wrong
This is a very early, small study with only 12 people, so results may not apply to everyone. It only looks at safety and drug levels, not whether the drug works for any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trials of Texas (CTT)
San Antonio, Texas, 78229, United States
-
Orlando Clinical Research Center (OCRC)
Orlando, Florida, 32809, United States
-
Texas Liver Institute (TLI)
San Antonio, Texas, 78215, United States